Vasar V, Appelberg B, Rimón R, Selvaratnam J
Department of Psychiatry, University of Tartu, Finland.
Int Clin Psychopharmacol. 1994 Sep;9(3):203-6. doi: 10.1097/00004850-199409000-00009.
Fluoxetine, a selective inhibitor of serotonin (5-HT) uptake, was compared with placebo in a randomized double-blind longitudinal trial in 12 healthy volunteers. Sleep polygraphic recordings were performed at home twice before and once after 6 days of medication. After 6 days fluoxetine significantly decreased the amount of rapid eye movement (REM) sleep. The sleep-onset latency and REM latency were increased, but there was no significant increase in the amount of awakenings during night. The relative proportion of stages 2 and 3 increased after fluoxetine administration, although there was no significant change with regard to total amount of slow-wave sleep. Fluoxetine did not induce prominent eye movements during non-rapid eye movement (NREM) sleep in this study. Results of the subjective assessment revealed tendencies of improved sleep and well-being in the fluoxetine group. It is concluded that a comparatively small dose of fluoxetine (20 mg/day) causes the same type of changes in REM sleep which are characteristic of most antidepressive drugs.
在一项针对12名健康志愿者的随机双盲纵向试验中，将5-羟色胺（5-HT）摄取的选择性抑制剂氟西汀与安慰剂进行了比较。在服药前在家进行两次睡眠多导记录，服药6天后进行一次。6天后，氟西汀显著减少了快速眼动（REM）睡眠量。睡眠起始潜伏期和REM潜伏期增加，但夜间觉醒量没有显著增加。服用氟西汀后，2期和3期的相对比例增加，尽管慢波睡眠总量没有显著变化。在本研究中，氟西汀在非快速眼动（NREM）睡眠期间未诱发明显的眼球运动。主观评估结果显示，氟西汀组有睡眠改善和幸福感增强的趋势。得出的结论是，相对小剂量的氟西汀（20毫克/天）会引起与大多数抗抑郁药物相同类型的REM睡眠变化。
